Dipankar Bhattacharjee has been appointed as the President and Chief utive of Teva Pharmaceutical Industries’ Global Generic Medicines Group, replacing Siggi Olafsson who is set to retire at the end of the first quarter of 2017.
As CEO of Teva Generics Europe, Bhattacharjee “has a proven track record of improving revenues and profitability, significantly increasing operating profit margins in the European generics business,” the world’s biggest generic drugmaker said in a statement.
I am honoured to lead the Global Generic Medicines Group, a business with a robust R&D pipeline, a talented team of employees, well-established relationships with business partners and customers and significant prospects for organic growth, said Bhattacharjee.
Under his leadership, Tevas European business demonstrated consistent improvement in sales and profits, establishing Teva as one of the premier generics companies in Europe. He has focused on improving and enhancing the European generics operations, leading a full European integration of Actavis Generics and overseeing successful new product launches. He will be based in the US.
Teva will benefit from Dipankars extensive experience in generics and specialty medicines, his financial and operational expertise and his deep understanding and appreciation for Tevas culture of innovation and our outstanding people,” said Erez Vigodman, Tevas President and Chief utive Officer.
Bhattacharjee joined the company as General manager of Teva UK in 2009. Before his stint at Teva, he served 15 years at Bausch + Lomb in various senior roles.